INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 414m ago
HOUSE PTR14m ago
SEC 13F14m ago
ROBINHOOD CHAIN14m ago
SEC FORM 4/Open-market saleVerified data

Gloria Melanie sold IMVT

Chief Operating Officer · Immunovant, Inc. · Common Stock

Side
SELL
Value
$72K
Shares
2,241
Price
$32.06
Executed
Oct 7, 2026
Disclosed
Oct 9, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Oct 7 executedOct 9, 2026 disclosed

IMVT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
27/ 100 · ROUTINE
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+4 / 25

    $72K reported value · 1.0% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+1 / 15

    Routine: 6 prior trades recorded in this security

  • Frequency & clustering+10 / 15

    2 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · IMVT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    25
    GT
    Girao TiagoChief Financial Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$188K
    6,606 sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    32
    SS
    Stout Jay SChief Technology Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$75K
    2,595 sh
    		Oct 21, 2026Oct 23, 2026
    traded Oct 21, 2026
    		+2dSEC FORM 4

    Evidence

    24
    VC
    Van Tuyl ChristopherChief Legal Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$43K
    1,327 sh
    		Oct 7, 2026Oct 9, 2026
    traded Oct 7, 2026
    		+2dSEC FORM 4

    Evidence

    27
    SS
    Stout Jay SChief Technology Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$51K
    1,596 sh
    		Oct 7, 2026Oct 9, 2026
    traded Oct 7, 2026
    		+2dSEC FORM 4

    Evidence

    27
    SS
    Stout Jay SChief Technology Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$71K
    2,213 sh
    		Oct 7, 2026Oct 9, 2026
    traded Oct 7, 2026
    		+2dSEC FORM 4

    Evidence

    27
    VC
    Van Tuyl ChristopherChief Legal Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$103K
    2,846 sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    PA
    Pande AtulDirector
    IMVTImmunovant, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$65K
    1,500 sh
    		Aug 28, 2026Aug 28, 2026
    traded Aug 28, 2026
    		+0dSEC FORM 4

    Evidence

    0
    PA
    Pande AtulDirector
    IMVTImmunovant, Inc.
    Option exercise · 10b5-1 plan
    		M$13K
    1,500 sh
    		Aug 28, 2026Aug 28, 2026
    traded Aug 28, 2026
    		+0dSEC FORM 4

    Evidence

    0
    PA
    Pande AtulDirector
    IMVTImmunovant, Inc.
    Option exercise · 10b5-1 plan
    		M—
    1,500 sh
    		Aug 28, 2026Aug 28, 2026
    traded Aug 28, 2026
    		+0dSEC FORM 4

    Evidence

    25
    GM
    Gloria MelanieChief Operating Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$135K
    3,056 sh
    		Aug 20, 2026Aug 21, 2026
    traded Aug 20, 2026
    		+1dSEC FORM 4

    Evidence

    35
    SS
    Stout Jay SChief Technology Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$262K
    6,723 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    42
    SS
    Stout Jay SChief Technology Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$1.27M
    33.3K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    8
    GT
    Girao TiagoChief Financial Officer
    IMVTImmunovant, Inc.
    Option exercise
    		M$159K
    10.0K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    35
    GM
    Gloria MelanieChief Operating Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$116K
    2,966 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    42
    GM
    Gloria MelanieChief Operating Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$563K
    14.7K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    38
    GT
    Girao TiagoChief Financial Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$385K
    10.0K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    42
    VC
    Van Tuyl ChristopherChief Legal Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$572K
    15.0K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    0
    PA
    Pande AtulDirector
    IMVTImmunovant, Inc.
    Option exercise · 10b5-1 plan
    		M—
    1,500 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    23
    PA
    Pande AtulDirector
    IMVTImmunovant, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$57K
    1,500 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    0
    PA
    Pande AtulDirector
    IMVTImmunovant, Inc.
    Option exercise · 10b5-1 plan
    		M$13K
    1,500 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001764013-26-000112
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 7, 2026
    Published
    Oct 9, 2026
    Ingested by INSIDER
    Nov 5, 02:12 UTC
    Last re-read
    Nov 5, 02:12 UTC

    Extracted facts

    Filer
    Gloria Melanie
    Role
    Chief Operating Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Immunovant, Inc.
    Ticker
    IMVT
    Shares
    2,241
    Price per share
    $32.06
    Value
    $71,846
    Execution date (reported)
    Oct 7, 2026
    Owned after transaction
    217.1K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 2,241
    • Price: $32.06

    = $71,846

    What this establishes

    Gloria Melanie filed this Form 4 reporting a open-market sale of IMVT on Oct 7, 2026. It became public on Oct 9, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Operating Officer
    Gloria Melaniecik:0001973838
    Issuer
    Immunovant, Inc.cik:0001764013

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.